ClinicalTrials.gg
CompletedNCT01507831Updated Dec 22, 2015Results posted

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 320 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-22.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,341
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
Largest of 43
2,341 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
9th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one has the largest enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 9th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT).

Secondary Objectives:

  • To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.
  • To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points.
  • To evaluate the effects of alirocumab on other lipid parameters.
Read the detailed description

The maximum study duration was to be 89 weeks per participant, including a 3-week screening period, a 78-week randomized treatment period and 8-week follow-up period.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Either A or B below and who were not adequately controlled with their lipid-modifying therapy:

A) Participants with heterozygous familial hypercholesterolemia (heFH) with or without established coronary heart disease (CHD) or CHD risk equivalents

OR

B) Participants with hypercholesterolemia together with established CHD or CHD risk equivalents.

Exclusion criteria

Exclusion criteria:

  • Age \< 18 years
  • LDL-C \<70 mg/dL (\< 1.81 mmol/L)
  • Fasting serum triglycerides > 400 mg/dL (>4.52 mmol/L)

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,341 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.

    Drug: Placebo (for alirocumab) · Drug: Lipid-Modifying Therapy (LMT)

  • Experimental
    Alirocumab

    Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.

    Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)

Interventions

  • DrugPlacebo (for alirocumab)

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

  • Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

    Also known as: SAR236553, REGN727, Praluent

  • Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Adverse Events (AEs)

    Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).

    Time frame: Up to 10 weeks after last study drug administration (maximum of 86 weeks)

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

    Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

    Time frame: From Baseline to Week 52

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  4. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  5. Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis

    Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  6. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  7. Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  8. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  9. Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  10. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  11. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  12. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  13. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  14. Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

    Very high CV risk: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents or non- Familial Hypercholesterolemia (FH). High CV risk: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in imputation model.

    Time frame: Up to Week 52

  15. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: Up to Week 52

  16. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: Up to Week 52

  17. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: Up to Week 52

  18. Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment were included in the imputation model.

    Time frame: From Baseline to Week 52

  19. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  20. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  21. Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  22. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  23. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  24. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  25. Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

Other outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

    Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  3. Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis

    Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 78

  4. Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 78

  5. Percentage of Participants Who Experienced Cardiovascular (CV) Events

    CV events included coronary heart disease (CHD) death; non-fatal myocardial infarction (MI); fatal and non-fatal ischemic stroke; unstable angina requiring hospitalization; congestive heart failure (CHF) requiring hospitalization; ischemia-driven coronary revascularization procedure. Reported events are CV events as confirmed by an independent Clinical Events Committee (CEC) that occurred during the treatment emergent period ( i.e. from first dose up to the last dose of study drug + 70 days).

    Time frame: Up to 10 weeks after last study drug administration (maximum of 86 weeks)

07

Results

Posted Dec 22, 2015
Limitations and caveats
Manual reclassification was done by the Sponsor for the "other reasons" of non-completion of study as specified in the electronic case report (eCRF) form.

Participant flow

The study was conducted at 320 centers in 27 countries. Overall, 5144 participants were screened between January 2012 and March 2013, 2801 of whom were screen failures. Screen failures were mainly due to exclusion criteria met. In addition 2 participants received study drug but did not undergo randomization. They were excluded from analysis.

Participant flow — Overall Study
MilestonePlacebo Q2WAlirocumab 150 mg Q2W
Started7881553
Treated7881550
Completed5951113
Not completed193440
Withdrew: Randomized but not treated03
Withdrew: Adverse event48113
Withdrew: Death62
Withdrew: Poor compliance to protocol3860
Withdrew: Physician decision04
Withdrew: Participant moved519
Withdrew: Consent withdrawn by participant3472
Withdrew: Related to study drug administration514
Withdrew: Last visit outside protocol visit window51143
Withdrew: Selection criteria finally not met01
Withdrew: Site closure03
Withdrew: Potential lost to follow-up30
Withdrew: Other36

Outcome measures

PrimaryPercentage of Participants Who Experienced Adverse Events (AEs)

Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).

Time frame:
Up to 10 weeks after last study drug administration (maximum of 86 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Adverse Events (AEs)
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Any AE82.581.0
Any Serious AE19.518.7
Any AE leading to death1.30.5
Any AE leading to treatment discontinuation5.87.2
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis0.8 ± 1.0-61.0 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -61.9 · 95% CI -64.3 to -59.4Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis0.7 ± 1.0-62.8 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -63.5 · 95% CI -65.9 to -61.2Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis1.5 ± 1.0-63.3 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -64.8 · 95% CI -67.2 to -62.4Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis1.4 ± 1.0-64.2 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -65.5 · 95% CI -67.9 to -63.2Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis3.5 ± 1.1-57.8 ± 0.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -61.3 · 95% CI -64.0 to -58.5Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis1.2 ± 1.0-52.8 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -54.0 · 95% CI -56.3 to -51.7Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis1.2 ± 0.9-54.3 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -55.5 · 95% CI -57.7 to -53.2Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis0.7 ± 0.9-51.6 ± 0.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -52.3 · 95% CI -54.4 to -50.2Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis0.6 ± 0.9-53.1 ± 0.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -53.7 · 95% CI -55.7 to -51.6Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-0.3 ± 0.7-37.8 ± 0.5
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -37.5 · 95% CI -39.1 to -35.9Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis0.5 ± 0.9-55.5 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -56.0 · 95% CI -58.3 to -53.7Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis0.9 ± 0.8-53.7 ± 0.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -54.6 · 95% CI -56.6 to -52.6Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis0.2 ± 0.6-38.8 ± 0.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -39.0 · 95% CI -40.4 to -37.5Alirocumab vs. Placebo
SecondaryPercentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

Very high CV risk: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents or non- Familial Hypercholesterolemia (FH). High CV risk: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in imputation model.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis8.580.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 71.5 · 95% CI 51.6 to 99.1Alirocumab vs. Placebo
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis8.582.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 93.4 · 95% CI 66.1 to 132.0Alirocumab vs. Placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis8.079.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 74.6 · 95% CI 53.3 to 104.4Alirocumab vs. Placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis8.081.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 97.3 · 95% CI 68.2 to 138.9Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment were included in the imputation model.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis-3.7 ± 1.0-29.3 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -25.6 · 95% CI -28.1 to -23.1Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis-0.6 ± 0.54.0 ± 0.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 4.6 · 95% CI 3.3 to 5.9Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis1.8 ± 1.2-15.6 ± 0.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -17.3 · 95% CI -20.1 to -14.6Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo A1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis1.2 ± 0.64.0 ± 0.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 2.9 · 95% CI 1.6 to 4.2Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis-3.1 ± 1.0-28.2 ± 0.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -25.1 · 95% CI -27.4 to -22.7Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis0.2 ± 0.55.8 ± 0.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 5.6 · 95% CI 4.3 to 6.8Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis1.2 ± 1.1-16.7 ± 0.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -17.9 · 95% CI -20.5 to -15.3Alirocumab vs. Placebo
SecondaryPercent Change From Baseline in Apo A1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis0.6 ± 0.54.6 ± 0.3
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: 4.0 · 95% CI 2.8 to 5.2Alirocumab vs. Placebo
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis4.4 ± 1.2-56.8 ± 0.8
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis4.6 ± 1.1-59.9 ± 0.8
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis

Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 78
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis3.6 ± 1.3-52.4 ± 0.9
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 78
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis3.9 ± 1.2-58.0 ± 0.9
Other pre-specifiedPercentage of Participants Who Experienced Cardiovascular (CV) Events

CV events included coronary heart disease (CHD) death; non-fatal myocardial infarction (MI); fatal and non-fatal ischemic stroke; unstable angina requiring hospitalization; congestive heart failure (CHF) requiring hospitalization; ischemia-driven coronary revascularization procedure. Reported events are CV events as confirmed by an independent Clinical Events Committee (CEC) that occurred during the treatment emergent period ( i.e. from first dose up to the last dose of study drug + 70 days).

Time frame:
Up to 10 weeks after last study drug administration (maximum of 86 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Cardiovascular (CV) Events
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Participants Who Experienced Cardiovascular (CV) Events5.14.6
Post-hocPercentage of Participants Who Experienced Major Adverse CV Events

Major adverse CV events were defined as all adverse CV events except Congestive heart failure (CHF) requiring hospitalization; and ischemia-driven coronary revascularization procedure.

Time frame:
Up to 10 weeks after last study drug administration (maximum of 86 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Major Adverse CV Events
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Participants Who Experienced Major Adverse CV Events3.31.7

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 86 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—154/788 (19.5%)366/788 (46.4%)
Alirocumab 150 mg Q2W—290/1,550 (18.7%)707/1,550 (45.6%)
Most frequent serious events
Showing 10 of 333
Most frequent serious events
EventPlacebo Q2WAlirocumab 150 mg Q2W
Angina unstableCardiac disorders9/78829/1550
Acute myocardial infarctionCardiac disorders11/7889/1550
PneumoniaInfections and infestations7/7886/1550
Atrial fibrillationCardiac disorders7/7889/1550
Non-cardiac chest painGeneral disorders2/78813/1550
SyncopeNervous system disorders6/78811/1550
Angina pectorisCardiac disorders6/7889/1550
Acute coronary syndromeCardiac disorders6/7882/1550
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders6/7884/1550
Coronary artery diseaseCardiac disorders3/78810/1550
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo Q2WAlirocumab 150 mg Q2W
NasopharyngitisInfections and infestations103/788209/1550
Upper respiratory tract infectionInfections and infestations68/788114/1550
Urinary tract infectionInfections and infestations54/78887/1550
Back painMusculoskeletal and connective tissue disorders52/78884/1550
ArthralgiaMusculoskeletal and connective tissue disorders52/78880/1550
Injection site reactionGeneral disorders33/78891/1550
DiarrhoeaGastrointestinal disorders45/78889/1550
InfluenzaInfections and infestations43/78888/1550
HeadacheNervous system disorders44/78876/1550
MyalgiaMusculoskeletal and connective tissue disorders23/78884/1550

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WAlirocumab 150 mg Q2WTotal
Mean60.6 ± 10.460.4 ± 10.460.5 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WAlirocumab 150 mg Q2WTotal
Female314570884
Male4749831457
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo Q2WAlirocumab 150 mg Q2WTotal
Mean121.9 ± 41.4122.7 ± 42.6122.4 ± 42.2
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Placebo Q2WAlirocumab 150 mg Q2WTotal
Mean3.157 ± 1.0733.178 ± 1.1023.171 ± 1.092
08

Study locations

320 sites
  • Investigational Site Number 840159
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840028
    Gilbert, Arizona 85295, United States
  • Investigational Site Number 840035
    Sierra Vista, Arizona 85635, United States
  • Investigational Site Number 840052
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840065
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840079
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840094
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840103
    Tucson, Arizona 85741-3565, United States
  • Investigational Site Number 840209
    Beverly Hills, California 90210, United States
  • Investigational Site Number 840194
    Beverly Hills, California 90211, United States
  • Investigational Site Number 840207
    Fresno, California 93720, United States
  • Investigational Site Number 840101
    Lincoln, California 95648, United States
  • Investigational Site Number 840076
    Long Beach, California 90807, United States
  • Investigational Site Number 840214
    Pasadena, California 91105, United States
  • Investigational Site Number 840045
    Sacramento, California 95842, United States
  • Investigational Site Number 840163
    Santa Rosa, California 95405, United States
  • Investigational Site Number 840086
    Colorado Springs, Colorado 80906, United States
  • Investigational Site Number 840077
    Golden, Colorado 80401, United States
  • Investigational Site Number 840224
    Bridgeport, Connecticut 06610, United States
  • Investigational Site Number 840134
    Guilford, Connecticut 06437, United States
  • Investigational Site Number 840246
    Hartford, Connecticut 06102, United States
  • Investigational Site Number 840055
    Stamford, Connecticut 06905, United States
  • Investigational Site Number 840091
    Stamford, Connecticut 06905, United States
  • Investigational Site Number 840150
    Atlantis, Florida 33462, United States
  • Investigational Site Number 840020
    Bradenton, Florida 34208, United States
  • Investigational Site Number 840041
    Brandon, Florida 33511, United States
  • Investigational Site Number 840184
    Clearwater, Florida 33756, United States
  • Investigational Site Number 840242
    Clearwater, Florida 33756, United States
  • Investigational Site Number 840039
    Clearwater, Florida 33765, United States
  • Investigational Site Number 840182
    Crystal River, Florida 34429, United States
  • Investigational Site Number 840002
    Daytona Beach, Florida 32117, United States
  • Investigational Site Number 840166
    Daytona Beach, Florida 32117, United States
  • Investigational Site Number 840167
    Fleming Island, Florida 32003, United States
  • Investigational Site Number 840018
    Fort Lauderdale, Florida 33309, United States
  • Investigational Site Number 840090
    Ft. Lauderdale, Florida 33308, United States
  • Investigational Site Number 840153
    Jacksonville, Florida 32204, United States
  • Investigational Site Number 840181
    Jacksonville, Florida 32205, United States
  • Investigational Site Number 840152
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840154
    Lake Mary, Florida 32746, United States
  • Investigational Site Number 840059
    Largo, Florida 33773, United States
  • Investigational Site Number 840221
    Miami, Florida 33176, United States
  • Investigational Site Number 840021
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840122
    New Smyrna Beach, Florida 32169, United States
  • Investigational Site Number 840151
    Ocala, Florida 34471, United States
  • Investigational Site Number 840108
    Ormond Beach, Florida 32174, United States
  • Investigational Site Number 840067
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840006
    Pembroke Pines, Florida 33026, United States
  • Investigational Site Number 840168
    Ponte Vedra, Florida 32081, United States
  • Investigational Site Number 840164
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840175
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840001
    St. Petersburg, Florida, United States
  • Investigational Site Number 840003
    St. Petersburg, Florida, United States
  • Investigational Site Number 840036
    West Palm Beach, Florida 33401, United States
  • Investigational Site Number 840117
    Cumming, Georgia 30041, United States
  • Investigational Site Number 840110
    Roswell, Georgia 30076, United States
  • Investigational Site Number 840026
    Savannah, Georgia 31405, United States
  • Investigational Site Number 840075
    Meridian, Idaho 83646, United States
  • Investigational Site Number 840027
    Evansville, Indiana 47714, United States
  • Investigational Site Number 840093
    Indianapolis, Indiana 46260, United States
  • Investigational Site Number 840222
    Iowa City, Iowa 52242, United States
  • Investigational Site Number 840165
    West Des Moines, Iowa 50266, United States
  • Investigational Site Number 840200
    Kansas City, Kansas 66160-7321, United States
  • Investigational Site Number 840040
    Wichita, Kansas 67203, United States
  • Investigational Site Number 840061
    Wichita, Kansas 67205, United States
  • Investigational Site Number 840032
    Wichita, Kansas 67207, United States
  • Investigational Site Number 840084
    Wichita, Kansas 67207, United States
  • Investigational Site Number 840244
    Biddeford, Maine 04005, United States
  • Investigational Site Number 840158
    Framingham, Maine 01702, United States
  • Investigational Site Number 840193
    Novi, Michigan 48374, United States
  • Investigational Site Number 840162
    Saginaw, Michigan 48604, United States
  • Investigational Site Number 840033
    Saint Louis, Missouri 63117, United States
  • Investigational Site Number 840113
    St. Louis, Missouri 63131, United States
  • Investigational Site Number 840095
    Henderson, Nevada 89052, United States
  • Investigational Site Number 840096
    Henderson, Nevada 89052, United States
  • Investigational Site Number 840022
    Edison, New Jersey 08817, United States
  • Investigational Site Number 840011
    Hillsborough, New Jersey 08844, United States
  • Investigational Site Number 840049
    Trenton, New Jersey 08611, United States
  • Investigational Site Number 840097
    Bronxville, New York 10708, United States
  • Investigational Site Number 840129
    Brooklyn, New York 11215, United States
  • Investigational Site Number 840160
    Poughkeepsie, New York 12601, United States
  • Investigational Site Number 840217
    Asheville, North Carolina 28803, United States
  • Investigational Site Number 840023
    Charlotte, North Carolina 28211, United States
  • Investigational Site Number 840083
    Greensboro, North Carolina 27408, United States
  • Investigational Site Number 840104
    Raleigh, North Carolina 27609, United States
  • Investigational Site Number 840068
    Cincinnati, Ohio 45236, United States
  • Investigational Site Number 840007
    Dayton, Ohio 45406, United States
  • Investigational Site Number 840013
    Marion, Ohio 43302, United States
  • Investigational Site Number 840161
    Mentor, Ohio 44060, United States
  • Investigational Site Number 840005
    Tulsa, Oklahoma 74136, United States
  • Investigational Site Number 840170
    Beaver, Pennsylvania 15009, United States
  • Investigational Site Number 840180
    Camp Hill, Pennsylvania 17011, United States
  • Investigational Site Number 840004
    Duncansville, Pennsylvania 16635, United States
  • Investigational Site Number 840046
    Jersey Shore, Pennsylvania 17740, United States
  • Investigational Site Number 840155
    Phoenixville, Pennsylvania 19460, United States
  • Investigational Site Number 840177
    Scranton, Pennsylvania 18508, United States
  • Investigational Site Number 840202
    Wyomissing, Pennsylvania 19610, United States
  • Investigational Site Number 840073
    Charleston, South Carolina 29485, United States
  • Investigational Site Number 840087
    Greenville, South Carolina 29615, United States
  • Investigational Site Number 840074
    Simpsonville, South Carolina 29681, United States
  • Investigational Site Number 840105
    Varnville, South Carolina 29944, United States

Showing the first 100 of 320 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. PubMed 25773378 ↗
  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4. Erratum In: J Clin Lipidol. 2020 Sep - Oct;14(5):742. doi: 10.1016/j.jacl.2020.09.010. PubMed 28964736 ↗
  • Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Jan-Feb;11(1):195-203.e4. doi: 10.1016/j.jacl.2016.12.004. Epub 2016 Dec 28. PubMed 28391886 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
Jan 11, 2012
Start
Jan 2012
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Dec 22, 2015
Last update
Dec 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01507831
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 11, 2012
Start date
Jan 2012
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Dec 22, 2015
Last update
Dec 22, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion